Company intelligence / Profile preview

Door Pharmaceuticals

Bloomington, Indiana, United States

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Door Pharmaceuticals is developing a novel class of antivirals called reactive capsid assembly modulators (rCAMs) for chronic Hepatitis B virus. The company has demonstrated that small molecules binding to HBV core protein can suppress HBV production, potentially by inhibiting viral RNA transcription. As of 2024, the company received Phase I SBIR funding ($306,500) to develop rCAMs that target viral nucleic acids for destruction by concentrating reactive components near viral DNA and RNA.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Indiana University

Beyond the preview

Go deeper on Door Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Door Pharmaceuticals.

Explore the full profile